Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update
Clinical Pharmacology & Therapeutics2016Vol. 102(1), pp. 37–44
Citations Over TimeTop 1% of 2016 papers
JK Hicks, Katrin Sangkuhl, JJ Swen, VL Ellingrod, Müller Dj, Kazutaka Shimoda, JR Bishop, E D Kharasch, TC Skaar, Andrea Gaedigk, Henry M. Dunnenberger, Teri E. Klein, KE Caudle, Julia Stingl
Abstract
CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline, clomipramine, doxepin, imipramine, and trimipramine). Evidence is presented for CYP2D6 and CYP2C19 genotype-directed dosing of TCAs. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants.
Related Papers
- → Towards the implementation ofCYP2D6andCYP2C19genotypes in clinical practice: Update and report from a pharmacogenetic service clinic(2013)83 cited
- → The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort(2020)26 cited
- → The Effect of CYP2C19 and CYP2D6 Genotypes on the Metabolism of Clomipramine in Japanese Psychiatric Patients(2001)42 cited
- Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry.(2006)
- → Serum Clomipramine and Desmethylclomipramine Levels in a CYP2C19 and CYP2D6 Intermediate Metabolizer(2017)8 cited